Merck Pushes Discount Zocor; Health Plans Are Wary, But Pfizer Is Concerned
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
You may also be interested in...
UnitedHealth will drop AstraZeneca's brand from coverage after competition drives down price of generic rosuvastatin.
In China, multinational pharmaceutical companies are not so worried about the patent cliff, as many off-patent products enjoy premium pricing and high-growth rates even when dozens of generics exist. But how long will the party last?
Watson is progressing on a multi-year effort to diversify beyond its core U.S. generics business into branded drugs and international markets.